
-
What are regulatory T-cells? Nobel-winning science explained
-
Indirect talks on ending Gaza war begin in Sharm El-Sheikh: Egypt media
-
OpenAI signs multi-billion dollar chip deal with AMD
-
Salah under fire as Liverpool star loses his spark
-
Paris stocks drop as French PM resigns, Tokyo soars
-
ICC finds Sudan militia chief guilty of crimes against humanity
-
Zverev dumped out of Shanghai Masters by France's Rinderknech
-
One hiker dead, hundreds rescued after heavy snowfall in China
-
Hundreds stage fresh anti-government protests in Madagascar
-
Feminist icon Gisele Pelicot back in court as man appeals rape conviction
-
US government shutdown enters second week
-
Kasatkina ends WTA season early after hitting 'breaking point'
-
Paris stocks drop as French PM resigns
-
Death toll from Indonesia school collapse rises to 63
-
Medicine Nobel to trio who identified immune system's 'security guards'
-
UN rights council launches probe into violations in Afghanistan
-
UK author Jilly Cooper dies aged 88
-
Jilly Cooper: Britain's queen of the 'bonkbuster' novel
-
Streaming stars' Le Mans race scores Twitch viewer record
-
England rugby star Moody 'shocked' by motor neurone disease diagnosis
-
Leopard captured after wandering into Indonesian hotel
-
Israel, Hamas due in Egypt for ceasefire talks
-
Rescuers scramble to deliver aid after deadly Nepal, India floods
-
Tokyo stocks soar on Takaichi win, Paris sinks as French PM resigns
-
OpenAI offers more copyright control for Sora 2 videos
-
Australia prosecutors appeal 'inadequate' sentence for mushroom murderer: media
-
Rugby World Cup-winning England star Moody has motor neurone disease
-
Trump says White House to host UFC fight on his 80th birthday
-
Vast reserves, but little to drink: Tajikistan's water struggles
-
US government shutdown may last weeks, analysts warn
-
Arsenal host Lyon to start new Women's Champions League format
-
Gloves off, Red run, vested interests: Singapore GP talking points
-
Bills, Eagles lose unbeaten records in day of upsets
-
Muller on target as Vancouver thrash San Jose to go joint top
-
Tokyo soars, yen sinks after Takaichi win on mixed day for Asia
-
China's chip challenge: the race to match US tech
-
UN rights council to decide on creating Afghanistan probe
-
Indonesia sense World Cup chance as Asian qualifying reaches climax
-
ICC to give war crimes verdict on Sudan militia chief
-
Matthieu Blazy to step out as Coco's heir in Chanel debut
-
Only man to appeal in Gisele Pelicot case says not a 'rapist'
-
Appetite-regulating hormones in focus as first Nobel Prizes fall
-
Gisele Pelicot: French rape survivor and global icon
-
Negotiators due in Egypt for Gaza talks as Trump urges quick action
-
'My heart sank': Surging scams roil US job hunters
-
Competition heats up to challenge Nvidia's AI chip dominance
-
UK police to get greater powers to restrict demos
-
Valsoft Corporation Announces Creation of Operating Groups to Strengthen Portfolio Management and Long-Term Growth
-
Form Bio and Cure Rare Disease Partner to Accelerate Genetic Medicine Development, Advancing CRD's Duchenne Muscular Dystrophy Program
-
A $1 SIM Card Nearly Triggered America's Zero Day; Here's How SMX Could Stop the Next Attempt (NASDAQ: SMX)
RIO | 1.72% | 67.265 | $ | |
CMSC | -0.32% | 23.795 | $ | |
BTI | -0.41% | 51.03 | $ | |
SCS | -0.44% | 17.035 | $ | |
BCE | -0.73% | 23.19 | $ | |
NGG | 0% | 73.43 | $ | |
CMSD | -0.1% | 24.426 | $ | |
RBGPF | -2.92% | 76 | $ | |
BCC | -1.4% | 76.56 | $ | |
JRI | -0.48% | 14.231 | $ | |
GSK | 1.08% | 43.825 | $ | |
AZN | 0.84% | 86.03 | $ | |
RYCEF | -0.7% | 15.65 | $ | |
VOD | -0.68% | 11.283 | $ | |
RELX | 0.48% | 46.635 | $ | |
BP | 2.27% | 34.952 | $ |

Florence Announces AI-Assisted Workflows to Transform Clinical Trials
ATLANTA, GA / ACCESS Newswire / September 2, 2025 / Ahead of its premier life science event advancing Clinical Trial technology and innovation, Research Revolution, Florence Healthcare today announced its upcoming AI-centric workflows aimed at transforming clinical trials conducted across the study life-cycle. These solutions will significantly accelerate and enhance site identification, feasibility, start up, study conduct and remote monitoring for both sites and sponsors.
Built in collaboration with top sponsors, CRO partners, and hundreds of research sites; these new Human-in-loop (HITL) AI capabilities are built to supercharge clinical trial professionals as they tackle some of the most persistent challenges in the industry:
Limited Visibility Into Site Performance: Sponsors struggle to identify the right research sites, relying on disparate and stagnant data sources that provide limited visibility into true site capacity and performance.
Inefficient Study Start-Up Processes: Timelines are bogged down by manual and fragmented workflows and communication across stakeholders. Meaning critical data and documents are trapped in email chains, portals, and spreadsheets- causing version control issues, compliance risks, and inefficiencies.
Fragmented Oversight & Monitoring: Fragmented data and documents means that sponsor oversight is limited. Disparate systems prevent monitors from having real-time visibility into trial progress. As a consequence, costly physical site visits are still needed.
AI Assisted workflows will be available to Sponsors, CROs and Research Sites in October 2025
Florence Healthcare will introduce modules to directly address the challenges listed above. These will include:
Site Identification & Feasibility: Utilizing these new workflows, Sponsors will be able to quickly search across site profiles according to therapeutic area, geography, and real-time performance criteria to pick the right sites for study startup. From there they can deliver protocol-specific feasibility surveys, focusing on questions that are informative rather than repetitive. Sites will then be able to leverage an AI-driven workflow to accelerate survey completion with context-specific responses highlighting Site qualifications for the specific study.
Study Start-Up: New AI-driven contract negotiations will accelerate time to startup, in compliance with Site and Sponsor guidelines for contracts. In addition, a fully automated document exchange with Site eISF will provide the flexibility to tailor documents to specific Site networks or regions. The enhanced AI workflows will also simplify document management across startup and trial conduct, reducing administrative work for sites and sponsors.
Remote Monitoring: Remote Monitoring will also receive an AI upgrade. New reports providing deeper insights into Study progress across Sites or at specific sites will be available, allowing for quick intervention and remediation to keep trials on track, and obviating the need for physical site visits.
These AI-centric product workflows will enter limited availability in October 2025 for early adopters. These workflows are built on Florence's validated and GxP-compliant infrastructure-trusted by over 37,000 research sites globally. They include full audit traceability, 21 CFR Part 11 support, and interoperability APIs for CTMS, eTMF, and identity systems.
"We're not just automating the trial conduct for speed," said Shankar Jagannathan, COO at Florence. "We're creating a shared, AI-augmented experience between sponsors and sites to reduce manual work and increasing capacity, while minimizing risk -one that's more intelligent, scalable, and efficient."
About Florence Healthcare
Florence is a purpose-built platform that connects sponsors and sites to accelerate clinical trials, improve operational capacity, and reduce risk. Designed for scale, Florence streamlines workflows, enhances collaboration, and delivers real-time visibility across studies-empowering research teams to move faster, stay inspection-ready, and increase trial throughput with fewer resources.
For more information, visit www.florencehc.com
Press Contact:
Lautel Okhio
Communications, Florence
[email protected]
SOURCE: Florence Healthcare
View the original press release on ACCESS Newswire
M.Thompson--AMWN